- Home
- CRDL vs DIBS Comparison
CRDL vs DIBS Comparison
Compare CRDL & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- DIBS
- Stock Information
- Founded
- CRDL 2017
- DIBS 2000
- Country
- CRDL Canada
- DIBS United States
- Employees
- CRDL N/A
- DIBS N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- DIBS Catalog/Specialty Distribution
- Sector
- CRDL Health Care
- DIBS Consumer Discretionary
- Exchange
- CRDL Nasdaq
- DIBS Nasdaq
- Market Cap
- CRDL 90.4M
- DIBS 94.6M
- IPO Year
- CRDL N/A
- DIBS 2021
- Fundamental
- Price
- CRDL $1.07
- DIBS $2.67
- Analyst Decision
- CRDL Strong Buy
- DIBS Hold
- Analyst Count
- CRDL 2
- DIBS 1
- Target Price
- CRDL $9.00
- DIBS N/A
- AVG Volume (30 Days)
- CRDL 781.9K
- DIBS 62.2K
- Earning Date
- CRDL 11-13-2025
- DIBS 11-07-2025
- Dividend Yield
- CRDL N/A
- DIBS N/A
- EPS Growth
- CRDL N/A
- DIBS N/A
- EPS
- CRDL N/A
- DIBS N/A
- Revenue
- CRDL N/A
- DIBS $88,640,000.00
- Revenue This Year
- CRDL N/A
- DIBS $2.87
- Revenue Next Year
- CRDL N/A
- DIBS $3.26
- P/E Ratio
- CRDL N/A
- DIBS N/A
- Revenue Growth
- CRDL N/A
- DIBS 3.21
- 52 Week Low
- CRDL $0.77
- DIBS $2.30
- 52 Week High
- CRDL $2.24
- DIBS $4.72
- Technical
- Relative Strength Index (RSI)
- CRDL 44.73
- DIBS 44.32
- Support Level
- CRDL $1.04
- DIBS $2.52
- Resistance Level
- CRDL $1.16
- DIBS $2.86
- Average True Range (ATR)
- CRDL 0.06
- DIBS 0.09
- MACD
- CRDL 0.00
- DIBS -0.02
- Stochastic Oscillator
- CRDL 20.83
- DIBS 37.92
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.